BioSpace News Archive

Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, reported financial results for the year ended December 31, 2021 and provided a corporate update.

BioCopy AG introduces ValidaTe, an innovative, proprietary platform based on microarrays for the highly parallelized screening of drug candidates for T-cell therapy.

OSSIO, Inc. announced today that the company has achieved another significant commercial milestone with its third regulatory clearance from the U.S. Food and Drug Adminstration (FDA) for the OSSIOfiber® product family in the past four months, clearing a path to expand patient and surgeon access to additional implants made from OSSIOfiber® Intelligent Bone Regeneration Technology over the next six months.

Breast cancer is the world’s most commonly occurring cancer. According to Cancer.ca, breast cancer is the second leading cause of cancer deaths in Canadian women.

“I am pleased to announce the submission of our AcuVid™ COVID-19 Rapid Antigen Saliva Test for U.S. Food & Drug Administration’s Emergency Use Authorization,” shared Rob Fia, CEO of Therma Bright.

BioCurity is a private preclinical biotech company developing supportive cancer oncology drugs to prevent or mitigate some of the side effects of radiation therapy for cancer patients.

The National Cancer Institute-designated Albert Einstein Cancer Center has announced the appointment of three faculty members to key leadership positions, reflecting the center’s commitment to basic science, translational, and clinical research and its core principles of diversity, equity, and inclusion.

Vascular Therapies, Inc. today announced the closing of a $25 million private financing. The financing comprised of existing and new investors, including a Fortune 100 global healthcare company.

PharmaJet® announced the release of a video highlighting the recent implementation of a polio vaccination campaign in Somalia.

The global dental equipment market size is predicted to hit US$ 12.20 billion by 2029 and expected to drive growth at a CAGR of 8.7% from 2021 to 2030.